Journal profile · Immunology
NeuroImmunoModulation
ISSN 1021-7401 · eISSN 1423-0216 · S. Karger AG · SWITZERLAND · Bimonthly · Founded 1994
NeuroImmunoModulation: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.67; fully open access; APC about USD 2,540; median 87 days to acceptance (58 articles, last 24 months); community-reported acceptance: fairly easy; 27 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
NeuroImmunoModulation is published by S. Karger AG and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Stress Responses and Cortisol, Tryptophan and brain disorders and Neuroinflammation and Neurodegeneration Mechanisms, together about 33.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
The field of neuroimmunomodulation explores the way in which the nervous system interacts with the immune system via neural, hormonal and exosome microRNA actions and vice versa. Encompassing both basic and clinical research, Neuroimmunomodulation reports on all aspects of these interactions that bridge brain and immune system in bidirectional ways. The journal is also open to psychoneuroimmunology. Basic investigations consider all neural and humoral networks from molecular genetics/epigenetics through cell regulation to integrative systems of the body. Although primarily devoted to research articles, timely reviews on psycho-neuro-endocrine-immune interrelations are published on a regular basis.
From the journal's Aims & Scope
Research area (LetPub): Immunology
Editor-in-chief Rainer H. StraubPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Stress Responses and CortisolNeuroscience14%
- Tryptophan and brain disordersNeuroscience9.7%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience9.7%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance7.6%
- Human auditory perception and evaluationEngineering7.3%
- Immune Response and InflammationImmunology and Microbiology6.2%
- Neuropeptides and Animal PhysiologyNeuroscience4.4%
- Multiple Sclerosis Research StudiesMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 4 |
| Minor | Immunology | Zone 3 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.67LetPub ·
- Impact factor (publisher)
- 3.7Publisher website ·
- CiteScore 2026-06
- 5.5LetPub ·
- CiteScore (publisher)
- 5.5Publisher website ·
- SJR 2026-06
- 0.8LetPub ·
- SNIP 2026-06
- 0.7LetPub ·
- h-index
- 58LetPub ·
- h-index
- 88OpenAlex ·
- i10-index
- 893OpenAlex ·
- 2-year mean citedness
- 2.12OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 22LetPub ·
Articles by year OpenAlex count · 1,535 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 23 | 23 | 5 |
| 2025 | 27 | 27 | 75 |
| 2024 | 24 | 24 | 77 |
| 2023 | 36 | 36 | 401 |
| 2022 | 42 | 16 | 249 |
| 2021 | 65 | 13 | 882 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
87 daysMedian, submission to acceptance · P25–P75 62 days – 140 days
- Acceptance to online
- median 13 days (58 articles)
- Submission to online
- median 100 days
- Sample
- 58 articles with submission and acceptance dates (61 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 26%Publisher website ·
- Submission to first decision
- 14 daysPublisher website ·
- Submission to final decision
- 38 daysPublisher website ·
- Submission to publication (journal-reported)
- about 20 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | CHF 2,250 / USD 2,540 / EUR 2,230 | Yes | CC BY-NC | |
| Publisher website | USD 2,890 / USD 1,730 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websitePolicy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Self-archiving
- Authorship Author Contributions
In the Author Contribution statement, a short statement detailing the contributions of each person named as an author should be included. The CRediT taxonomy is a useful framework for preparing this section. Contributors to the submission who do not fulfil the ICMJE Criteria for Authorship should be credited, with their consent, in the Acknowledgement section.
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest Statement
Authors are required to disclose any relationship that could be perceived as a conflict of interest in the Conflict of Interest Statement. All forms of support and financial involvement which took place in the previous three years should be listed, regardless of their potential relevance to the paper. Nonfinancial relationships that may potentially influence the writing of the manuscript should al…
Source ↗Publisher website ·- Data availability Data Availability Statement
Authors are required to provide a Data Availability Statement that details whether data are publicly available and where the data supporting their study can be accessed. The journal’s data sharing policy strongly encourages authors to make all datasets on which the conclusions of the paper rely available to editors, reviewers and readers without unnecessary restriction wherever possible. In cases …
Source ↗Publisher website ·- License & copyright Licenses and Copyright
Articles published in Neuroimmunomodulation are licensed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, unless otherwise agreed with Karger Publishers. When sharing or reusing any article, attribution must be given to the original source, using the statement "The final, published version of this article is available at http://karger.com/?doi=[insert …
Source ↗Publisher website ·- Open access Gold Open Access Publication
Open Access license CC BY-NC 4.0 or funder-mandated license for manuscripts submitted from September 15, 2022 Model summary
All manuscripts submitted to the journal from September 15, 2022, and accepted for publication will carry the Open Access license CC BY-NC 4.0 or the license mandated by a funder. Upon acceptance, an Article Processing Charge (APC) will be levied.
Source ↗Publisher website ·- Peer review Peer Review
Peer Review Policy All Karger journals employ a rigorous peer-review process to confirm the validity and ensure scientific accuracy of published articles. Independent researchers with relevant expertise assess submitted manuscripts to help journal editors determine whether a manuscript should be published in their journal. All articles, except for Editorials and some Correspondence articles, are e…
Source ↗Publisher website ·- Self-archiving Archiving and Self-Archiving
All articles are archived in Portico. Articles may also be archived in PubMed Central if the journal is indexed there. Karger permits authors of Open Access articles to post the Version of Record (VOR) of their articles in Open Access repositories or on other websites. Preprints may be shared without restriction. Re-posted Open Access articles must follow the terms of the relevant Creative Commons…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- S. Karger AG
- Country or region
- SWITZERLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1994
- ISSN
- 1021-7401
- Electronic ISSN
- 1423-0216
- Society / sponsor
- GEBIN | German-Endocrine-Brain-Immune-Network
- Latest issue on the website
- Volume 33, Issue 1 (December 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about NeuroImmunoModulation
What CAS zone is NeuroImmunoModulation in?
In the 2025 upgraded edition of the CAS Journal Ranking, NeuroImmunoModulation is in Zone 4 of Medicine, and in Zone 4 of the minor category Endocrinology & Metabolism / Immunology / Neurosciences. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of NeuroImmunoModulation?
The latest impact factor listed by LetPub is 3.67; CiteScore 5.5, h-index 88.
How long does peer review take at NeuroImmunoModulation?
Based on the dates recorded on 58 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 87 days (interquartile range 62–140 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 26%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index NeuroImmunoModulation?
According to LetPub and DOAJ records, NeuroImmunoModulation is indexed in SCIE, Scopus and DOAJ.
Is NeuroImmunoModulation open access, and what is the APC?
NeuroImmunoModulation is a fully open-access journal. APC about USD 2,540.
Sources and updates
The facts on this page come from LetPub, Publisher website, DOAJ, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .